SOURCE: Eco-Rx, Inc.

November 29, 2007 08:00 ET

Eco-Rx Comments on the Rapid Spread of the MSRA Bacteria

NORTH MIAMI BEACH, FL--(Marketwire - November 29, 2007) - Eco-Rx (PINKSHEETS: ERXX), producer of proprietary air purification products, commented upon the editorial in the New York Times on November 20, 2007 entitled "Another Very Scary Germ." The editorial concludes that, "The discovery that MRSA is more prevalent than anyone thought reinforces the need for an aggressive, multipronged approach to curb the growing number of antibiotic-resistant bacteria." The conclusion reached in the October 17, 2007 issue of the Journal of American Medical Association (JAMA) stated, "Invasive MRSA infection affects certain populations disproportionately. It is a major public health problem primarily related to health care but no longer confined to intensive care units, acute care hospitals, or any health care institution."

Eco-Rx's President, Paul Taccini, commented, "We see a large and growing need for our products in the healthcare, commercial and residential markets to help combat the growing airborne bacterial danger posed to humans. The growing danger from these bacterial infections now extends into the home and schools. It cannot be emphasized too strongly that serious outbreaks of the MRSA bacteria within public facilities such as schools or hospitals can lead to serious illness or death. The Company is contacting towns and school systems which have experienced outbreaks of MSRA to make them aware of the RX 400's ability to kill over 99% of airborne bacterial agents on a 'first pass-through' basis."

In independent third party testing conducted by an EPA and FDA certified lab, the RX 400 killed greater than 99% of MRSA and other airborne bacteria on a 'first pass-through' basis. Additionally, the RX 400, is listed by the U S Food and Drug Administration (FDA) as a Class II Medical Device.

In a previous press release, Dr. Wladyslaw J. Kowalski, P.E., noted authority on indoor air quality, recently published an article in the September 2007 issue of Consulting-Specifying Engineer Magazine titled "Airborne Superbugs: Can Hospital Acquired Infections Cause Community Epidemics?" He stated, "Nosocomial infections have been around as long as hospitals have been operating...thanks to favorable indoor environments airborne epidemics tend to be self-perpetuating, as opposed to food-borne and water-borne epidemics, which tend to be local and short-lived. Most of the drug resistant pathogens circulating today are capable of airborne transmission." Dr. Kowalski is Vice President for Immune Building Systems Inc. In addition, he conducts research for the Indoor Environment Center at The Pennsylvania State University and is chairman of the Air Treatment Group of the International Ultraviolet Association.

In the January 2007, HPAC Engineering Magazine, Dr. Kowalski also commented "With more than a third of all nosocomial-infections possibly involving airborne transmission at some point, the combination of surface and air disinfection should produce optimum results."

Please visit our web site ECO-RX.COM for additional information about the technology and its capabilities.

About Eco-Rx

Eco-Rx, Inc. produces proprietary products utilizing a patented, high-intensity ultraviolet radiation (UVC) system with an easy to use replaceable cartridge. The UVC destroys airborne bacteria. Extensive independent testing by an EPA and FDA certified laboratory confirms that the unique technology kills airborne bacteria including: Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiella pneumoniae. The machine does not produce nor use ozone. Eco-Rx combines its purification technology, a sophisticated electronic ballast system, with an electronic control module in a product that is totally effective and user-friendly. The technology uses a replaceable cartridge providing 12 months of continuous operation (24/7).

Disclaimer

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include expectations which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Factors that might cause or contribute to such differences include, but are not limited to: difficulties encountered in launching a new product, competition and receiving timely shipments from the manufacturer in China. Eco-Rx undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contact Information

  • Contact person:
    Joe Peiken
    305.937.1862